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 ABSTRACT 
 The objective of the study was to evaluate premilking 
teat disinfectant efficacy with the use of a novel diag-
nostic protocol against a positive control. The evalua-
tion of efficacy was based on establishing noninferiority 
of a new premilking teat disinfectant compared with 
an existing premilking teat disinfectant. Approximately 
200 cows were randomly allocated to 1 of 2 groups. 
Study personnel were blinded as to cow allocation and 
identification of the premilking disinfectants. Quar-
ters were disinfected using a dip cup before milking 
with either the control or experimental product. The 
disinfectant was left on the teat for approximately 30 
s before being wiped off in preparation for milking. 
Quarter-level bacteriological infection status was estab-
lished at the beginning of the study and quarter milk 
samples were collected biweekly thereafter. Bacterio-
logical analyses were performed only when somatic cell 
counts in milk samples crossed a parity-specific thresh-
old. Poisson regression models were used to analyze 
data. The difference in the rate of new intramammary 
infections was small and the upper bound of the 95% 
confidence interval of the rate difference was smaller 
than a predefined noninferiority limit. Based on the ob-
served difference in new intramammary infections rate 
between the experimental and control product, it was 
concluded that the experimental disinfectant was not 
inferior compared with the positive control. The proto-
col used in this study proposes a valid and economically 
attractive methodology to evaluate the efficacy of teat 
disinfectants relative to a positive control. 
 Key words:   teat disinfectant ,  iodine ,  intramammary 
infection ,  noninferiority 
 INTRODUCTION 
 A vast number of publications referring to the effec-
tiveness of pre- and postmilking teat disinfection prod-
ucts are available, documenting the importance of teat 
disinfection as a management tool in preventing new 
IMI with major pathogens in dairy cows (Boddie et 
al. 2000; Peters et al., 2000; Oliver et al., 2001; NMC, 
2013). In many of these initial studies, iodine teat dips 
have proven to be effective at reducing the incidence 
of new IMI with mastitis-causing pathogens (i.e., Pan-
key et al., 1987). As a consequence, the success of teat 
disinfection has resulted in the emergence of numerous 
germicidal products marketed as teat disinfectants, 
creating a need for a formal efficacy estimation proto-
col. To standardize the evaluation of efficacy of these 
germicides, the National Mastitis Council (NMC) has 
developed several protocols over the years for both ex-
perimental and natural challenge conditions (Schukken 
et al., 2013). The NMC publishes annually a list of teat 
disinfection products that have been tested using these 
standardized protocols (NMC, 2013). 
 Postmilking teat disinfection has proven to be an effi-
cacious method to prevent IMI caused by Streptococcus 
agalactiae and Staphylococcus aureus compared with no 
postmilking teat sanitation (Neave et al., 1969; Foret 
et al., 2005, 2006). However, pathogens that reside 
primarily in the environment of the cow have not been 
controlled by postmilking teat sanitation (Pankey et 
al., 1987). One recommended approach to control envi-
ronmental mastitis is to decrease the bacterial load of 
teat ends to pathogens from the environment (Galton 
et al., 1984). A decrease in premilking bacterial loads 
on the teat skin can be obtained when teats are dipped 
with a disinfectant followed approximately 30 s later by 
wiping and drying teats with individual paper or cloth 
towels. 
 The NMC has published efficacy estimation protocols 
for teat disinfection products (Schukken et al., 2013), 
including a protocol for determining the efficacy of 
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premilking teat disinfectants (Hogan et al., 1991). This 
protocol for evaluation of premilking teat disinfectants 
is based on a negative control trial using naturally oc-
curring infections, identified through repeated monthly 
bacteriology in a 12-mo study. The proposed study 
design in this protocol lacks specific details, such as a 
precisely defined study protocol, appropriate power cal-
culations, and statistical analysis guidelines. The long 
prescribed duration of the study combined with the 
extensive culture-based diagnostics and low incidence 
of new IMI under field conditions would lead to very 
expensive trials. As a consequence, these standardized 
protocols are currently not routinely performed by 
manufacturers of premilking teat disinfectants. The 
suggested use of negative controls is also a limiting fac-
tor for the performance of these trials, as many owners 
of commercial dairy farms are not interested in end-
ing a practice that is generally considered valuable for 
their dairy. However, a need to formally and objectively 
evaluate premilking teat disinfectants exists. Therefore, 
a formal efficacy evaluation protocol for premilking 
teat disinfection of an experimental teat dip relative 
to a positive control product in reducing experimental 
challenge or naturally occurring IMI would be valuable.
Particularly in the case of premilking teat disinfec-
tant efficacy trials using naturally occurring IMI, the 
amount of diagnostics that is required to identify new 
IMI is large. As all quarters are disinfected postmilking 
in such trials, the expected rate of new IMI is low, re-
sulting in a predictably large number of bacteriological 
tests that are culture negative. For example, previous 
published studies reported 0.38 new IMI/100 quarter-
weeks in quarters that were disinfected premilking ver-
sus 0.64 new IMI/100 quarter-weeks in control quarters 
(Oliver et al., 2001). This study had a duration of 78 
wk (18 mo) in approximately 175 cows and resulted in a 
total of approximately 280 new IMI detected in an esti-
mated 13,000 quarter milk bacteriology tests. The costs 
of these diagnostics are high and it may be expected 
that such trials would generally be cost-prohibitive. As 
SCC testing is less expensive than bacteriology, and 
SCC above a given threshold increases the likelihood of 
identifying bacterial organisms substantially (Schepers 
et al., 1997), a 2-step diagnostic process for identifying 
new IMI is proposed. For example, Schepers et al. (1997) 
estimated that quarter milk SCC with a threshold of ei-
ther 100,000 or 200,000 SCC/mL had a sensitivity of 83 
and 75%, respectively, and a specificity of 81 and 90%, 
respectively, for diagnosing IMI. Indicating that, with 
SCC as an initial screen, approximately 80% of true 
IMI would be detected by bacteriological culture and 
only approximately 15% of uninfected quarters would 
incorrectly be subjected to bacteriological culture. Or, 
at the cost of not finding 20% of truly infected quarters, 
85% of uninfected quarters are not subjected to bacte-
riology. Using the overall incidence of approximately 
0.5 per 100 quarter-weeks in 175 cows from Oliver et al. 
(2001), the prescreening with SCC would result in 114 
quarters tested using bacteriology and 11 out of 14 IMI 
detected per sampling, compared with approximately 
700 quarters tested when using only bacteriological 
culture and 14 IMI detected. However, the use of such 
a 2-step diagnostic protocol has not been tried under 
natural infection conditions in commercial dairy herds.
The objective of this study was to use a novel 2-step 
diagnostic protocol to evaluate the efficacy of premilk-
ing teat disinfectant to reduce naturally occurring new 
IMI. We compared the efficacy of an experimental teat 
dip with that of a positive control product with the 
objective of showing noninferiority of the experimental 
premilking iodine-based teat disinfectant compared 
with an existing iodine-based premilking teat disinfec-
tant in commercial dairy herds.
MATERIALS AND METHODS
A 10-wk trial was conducted in a commercial dairy 
herd in western New York. Two groups of lactating cows 
with 100 and 99 animals each were selected. Cows were 
apparently in good health at the time of recruitment, 
based on a visual inspection of cows and udders, and 
had not been treated with antibiotics or anti-inflamma-
tory products in the 30 d before recruitment. The cows 
were housed in freestall barns and milked twice daily, 
following recommended premilking procedures (Schuk-
ken et al., 2013). Groups within the herd did not differ 
in feeding and management practices.
Selected cows were allocated to 1 of 2 groups (control 
= 100; experimental = 99). Groups were balanced by 
parity, DIM, and status of infection at the beginning of 
the trial. Study personnel were blinded to treatment al-
location and origin of the disinfectants. The same post-
milking teat disinfectant (Theratec Plus, GEA Farm 
Technologies Inc., Naperville, IL) was used for both 
study groups. The cows in the groups received either 
Theratec Plus [control group (CG)] or F-2326 [DeLaval 
Inc. Kansas City, MO; experimental group (EG)] as 
a premilking teat disinfectant. Pre- and postmilking 
products were all a ready-to-use 0.5% iodine teat disin-
fectant with emollients (5% glycerin) and were applied 
using a nonreturn dip cup.
Before the start of the trial, a site visit was conduct-
ed to train study personnel on study procedures. At 
the same time, the milking system was evaluated and 
checked whether the system met the criteria defined 
in the ISO standard procedure 6690:2007, “Milking 
machine installations – Construction and performance” 
(ISO, 2007). General information on farm management 
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practices were collected using a brief questionnaire. 
The adequacy of storage of teat disinfection mate-
rial was checked and found to be in compliance with 
manufacturer recommendations. Color-coded dip cups 
and matching leg bands were provided to the farm to 
further ensure proper treatment application during the 
trial.
Sample Collection and Laboratory Analysis
The efficacy of F-2326 compared with Theratec Plus 
was evaluated by defining the rate of new IMI in each 
study group. At the start of the study and whenever a 
cow entered the study, all quarters from each cow were 
aseptically sampled for aerobic culture and a second 
sample was taken for SCC. The entry sample was used 
to define the infection status or lack of infection (culture 
negative) in all quarters of the cows entering the study. 
Throughout the study period, 2 milk samples from each 
quarter were collected biweekly by trained technicians. 
One sample was always used for SCC analysis and a 
second sample was taken aseptically and stored under 
refrigeration for a maximum of 24 h until it was decided 
whether the sample was going to be used for aerobic 
culture. The results of the SCC analyses were used to 
decide whether the quarter sample would be submitted 
for bacteriological culture. The threshold for culturing 
was an SCC value > 100,000 cells/mL for first lactation 
cows and > 200,000 cells/mL for second and greater 
lactation cows. These thresholds for culturing were 
based on previously suggested optimal thresholds to 
distinguish infected from noninfected quarters (Laevens 
et al., 1997; Schepers et al., 1997). Over the course 
of the study, any quarter with clinical mastitis was 
sampled aseptically by farm personnel for bacterial cul-
ture before treatment was applied. Somatic cell count 
analyses were conducted at Dairy One (Ithaca, NY) 
using automated cell counting equipment (Fossomatic, 
Foss, Hillerød, Denmark). All aerobic cultures were con-
ducted at Quality Milk Production Services of Cornell 
University following standard protocols established by 
the NMC (Oliver et al., 2004). Briefly, approximately 
0.01 mL of milk was streaked on trypticase soy agar 
containing 5% sheep blood and 0.1% esculin (PML 
Microbiologicals, Mississauga, Canada) and plates were 
incubated aerobically at 37°C for 48 h. After observa-
tion of colony morphology and hemolytic patterns on 
blood agar, isolates were examined further by means 
of 3% KOH, Gram staining of organisms, catalase and 
oxidase testing, and additional biochemical and meta-
bolic evaluations as needed. Gram-negative organisms 
were identified by colony morphology on MacConkey’s 
agar (NMC, 1999).
Definition of New IMI
The initial bacteriological status of each quarter was 
established at the beginning of the trial using a single 
sample (Dohoo et al., 2011; Reyher and Dohoo, 2011). 
Once a quarter was identified as being infected with a 
particular organism, any repeat infection of the same 
quarter with the initially identified pathogen was not 
considered a new IMI. Therefore, an IMI was considered 
a new IMI based on the presence of a microorganism in 
a single quarter sample that was not identified in that 
quarter previously. Samples from clinical cases were 
considered eligible for identifying IMI. Once a new IMI 
was identified, the quarter became eligible for infection 
again for all organisms except the organisms that the 
quarter had been infected with before. Hence, a bacte-
rial organism not previously found in the same quarter 
would be eligible to cause a second or third new IMI. 
Samples containing more than 2 bacterial species were 
considered as contaminated and were not informative 
of IMI status.
Statistical Analysis
The incidence of new IMI during the whole study pe-
riod was calculated as the number of new IMI divided 
by the amount of quarter-time at risk for a new IMI 
across all time points. Efficacy of a teat disinfection 
product was evaluated in terms of reduction in the rate 
of new IMI observed among quarters disinfected with 
the experimental product compared with the rate ob-
served in control quarters (Nickerson et al., 2004). The 
efficacy is calculated as follows:
efficacy of experimental disinfectant = 1 −  
(rate of new IMI with experimental disinfectant/ 
 rate of new IMI with control product).  [1]
Note that if the rate of new IMI in the experimental 
disinfectant group is larger than the rate of new IMI 
in the positive control, the efficacy becomes negative 
and is defined at 0. The observed difference in the rate 
of new IMI between experimental and control disinfec-
tants with a 95% CI was calculated. The difference in 
rate and 95% CI were used for evaluation of noninfe-
riority. The study hypothesis was that no differences 
exist in the incidence of IMI between a control and 
experimental premilking iodine-based teat dips in re-
ducing naturally occurring infections.
The trial was designed as a positive control field 
trial, where the objective was to show noninferiority 
of the new product versus the existing product used 
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as control. Therefore, the main interest was to show a 
difference equal to zero (or a relative efficacy equal to 
zero). Even if the experimental product was slightly 
worse than the control product, the products may still 
be considered to be equivalent (Schukken et al., 2013). 
The experimental disinfectant was considered inferior 
only when the difference was larger than a determined 
critical value (Piaggio et al., 2006; Schukken et al., 
2013).
Efficacy of a premilking teat disinfectant for reduc-
ing new IMI relative to no premilking disinfection is 
estimated at approximately 50% (Pankey et al., 1987; 
Oliver et al., 2001). For an experimental product to 
be considered noninferior we need to define a nonin-
feriority margin (d). Using the data from the example 
above, a positive control would be expected to have an 
incidence of new IMI of approximately 1 new IMI per 
100 quarter-weeks. The upper 95% CI of the incidence 
of new IMI in the experimental group would need to be 
smaller than 1 + d new IMI per 100 quarter-weeks to 
conclude that the experimental teat disinfectant is non-
inferior to the positive control. The null and alternative 
hypothesis can then be formulated as
H0 = (rate new IMIexperimental − rate of new IMIcontrol)  
≥ d (experimental product is inferior), and HA =  
(rate new IMIexperimental − rate of new IMIcontrol)  
< d (experimental product is  
noninferior to control product).
For premilking teat disinfection trials, the posi-
tive control product should have a published efficacy 
against a negative control of approximately 50% or 
higher for the mastitis organisms of interest. Efficacy 
of premilking teat disinfectants meeting this ≥50% ef-
ficacy requirement have been reported (NMC, 2013). In 
general, we propose here that a premilking teat disin-
fection product is considered to be adequate if the left 
hand side of the 95% CI of the efficacy is at least 20%. 
The derivation of d, the maximum acceptable differ-
ence, can then be shown mathematically by defining pi 
= risk of IMI in group i, p1 = risk in test disinfectant, 
p2 = risk in negative control, and p3 = risk in positive 
control disinfectant. Note that we use risk and rate here 
interchangeably. The incidence of new IMI is measured 
per quarter-week at risk. As a short time period is the 
unit of analysis, the distinction between risk and rate 
diminishes. The relationship between risk (cumulative 
incidence) and rate is given by
risk = 1 − exp(− rate × Δt),
where Δt is measured in quarter-weeks. 
For small risk, a good approximation for risk is rate 
× Δt, and, hence, when risk is expressed as new IMI 
per week, rate and risk can be used interchangeably 
(Rothman et al., 2008). Therefore, we define 1 − (p1/
p2) > 0.2, and 1 − (p3/p2) = 0.5. Then p1/p2 = (p1/
p3) × (p3/p2), then, 1 − (0.5 × p1/p3) > 0.2 or p1/
p3 < 1.6. This means that the risk of infection in the 
test product group divided by the risk of infection in 
the positive control group should be less than 1.6. To 
relate this relative effect (efficacy is based on a ratio of 
2 infection risks) to the critical value of the difference 
between infection risk in treatment and positive control 
(d), d = p1 − p3 applies, for p1 ≤ 1.6 × p3 this becomes 
d = 1.6 × p3 − p3 = 0.6 × p3. With this definition of 
d, the study size can be calculated. For n = n1 = n3, 
the sample size per group (N) is given by (Christensen, 
2007)
 n = (Z2a + Zb)
2 × [p1(1 − p1) + p3 (1 − p3)]/d
2,  [2]
where Z is the standard normal distribution evaluated 
at either 2a or b, where 2a is twice the type I error and 
b is the type II error. Using an expected IMI risk in the 
positive control of approximately 1 new IMI per 100 
quarter-week (e.g., Oliver et al., 2001), a one-sided sig-
nificance level of 5%, and an estimated power of 80%, 
the trial size for a noninferiority study would have ap-
proximately 3,500 quarter-weeks per treatment group. 
Correction for the loss of diagnostic efficacy because 
of the prescreening with SCC (sensitivity estimated at 
80%), approximately 4,400 quarter-weeks per treatment 
group {[(1/0.8) × 3,500] would be needed, or about 100 
cows/treatment group for a 10–12-wk study}. The rela-
tionship between sample sizes, the defined value for d, 
and the power of the study is shown in Figure 1. In this 
figure, d is defined as either 0.004, 0.005, or 0.006 and 
the rate of new IMI in the positive control is defined 
at 1/100 quarter-weeks. The value of 0.006 for d (0.6 
× 0.01) relates to the arguments made in this paper; a 
value of 0.004 for d would imply that the minimum ef-
ficacy of premilking teat disinfectants against negative 
controls is defined at 30 rather than 20%, and for the 
shown d value of 0.005 the minimum efficacy would be 
25%.
The actual power for the trial was calculated post 
hoc when the study was completed and when the ac-
tual incidence of new IMI and the actual study size in 
quarter-weeks was known. The incidence rate of having 
a new IMI in cultured quarters was calculated as the 
rate that an individual quarter had a new IMI per unit 
of time considering only quarters eligible for a new IMI 
at any point in the trial (Table 1). It is thereby as-
sumed that, on average, an IMI takes place exactly in 
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the middle between 2 samplings. Prevalence of any IMI 
during the study period was calculated as the number 
of IMI at a given time point divided by the number of 
quarters sampled at that specific time point.
The quarter was the unit of interest accounting for 
within-cow and within-quarter clustering by fitting a 
generalized linear mixed model, including fixed effects 
of time and the interaction with treatment as categorical 
variables and quarter within cow as a repeated effect. 
Repeated measurements on the same individual are 
expected to lead to dependence between the responses 
of observations in a group (or cluster), such as con-
trol or experimental groups (Dohoo et al., 2009). This 
means that within-cow correlations of infection events 
should also be accounted for in the statistical analyses 
(Ceballos-Marquez et al., 2011). Analyses were carried 
out using PROC GLIMMIX in SAS version 9.2 (SAS 
Institute Inc., Cary, NC). This procedure fits statisti-
cal models to data with correlations or nonconstant 
variability and where the response is not necessarily 
Figure 1. Sample size and related power of the study in noninferiority studies per treatment group for an estimated incidence of new IMI of 
1 per 100 quarter-weeks at risk. The noninferiority limit is defined at 0.006, 0.005, and 0.004, related to a minimum efficacy of a test premilking 
disinfectant of 20, 25, and 30%, respectively. Color version available in the online PDF.
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normally distributed (Littell et al., 2006). The general-
ized linear mixed model used was
f [.] = intercept + treatment + time + (treatment  
 × time) + cow(random) + Re,  [3]
where f [.] is link function of the probability or rate of 
a new IMI. The probability of a new IMI is modeled 
in a logistic regression, whereas the rate of a new IMI 
is modeled in a Poisson regression. The link function is 
either a logit link when a binomial distribution is used 
or a log link for a Poisson distribution, treatment is 
teat disinfection product (control or experimental), and 
time corresponds to the time of milk sample collection 
relative to the cow entry into the trial. Time would be 
0, 2, 4, 6, 8, 10, or the actual wk of occurrence of a 
clinical case or a special sample, such as calving, dry-
off, or culling. For cows entering the trial after the start 
or cows leaving the trial before the completion of the 
study, less time would be included the study and the 
maximum time of 10 wk would not be reached. Cow is 
a random effect to correct for correlation within cow. 
Finally, Re is a complex error structure allowing for 
longitudinal within-quarter correlation. In the case of 
Poisson regression, a weighting factor was used describ-
ing the weeks at risk for each time period. Alterna-
tively, in the case of Poisson regressions, the number of 
new IMI per time period may be used as the outcome 
variable and an offset term with the natural log of the 
number of weeks at risk should be included in the ex-
planatory part of the model.
The coefficients of the regression models were ex-
pressed as odds ratios for the logistic regression and 
incidence rate ratios for the Poisson regression. Both 
of these parameters give the relative effect of predip-
ping with an experimental product on the incidence of 
new IMI across all quarters compared with a control 
product (Dohoo et al., 2009). The Wald’s test was used 
to determine statistical significance of individual terms 
in the regression model.
The dependent variable, SCC, obtained from each 
quarter sample (0, 2, 4, 6, 8, 10 wk after treatment), 
was analyzed using the linear mixed model
log10 (SCC) = intercept + treatment + time  
 + treatment × time + cow(random) + Re,  [4]
where log10 (SCC) is the base 10 log of the measured 
quarter SCC in thousands per milliliter, and the fixed 
and random effects in the model are the same as in 
model [3]. Final analyses were carried out using PROC 
MIXED in SAS version 9.2 (SAS Institute Inc.). For 
all analyses, a P-value of 0.05 was used for deciding on 
statistical significance.
RESULTS
The study in the herd took place between February 
and May, and the trial performance was without issues. 
Table 1. Examples for a third-lactation cow of coding individual quarters of a cow, SCC, bacteriology, the defined eligibility for a new IMI, 
and the observed occurrence of a new IMI1  
Cow Quarter
Time 
(wk)
SCC 
(1,000/mL) Bacteriology
Week  
at risk
New  
IMI Remark2
1 LF 0 12 Negative 0 0 Healthy quarter, at risk for new IMI with any pathogen
1 LF 2 19 NC 2 0 Healthy quarter, at risk for new IMI with any pathogen
1 LF 4 46 NC 2 0 Healthy quarter, at risk for new IMI with any pathogen
1 LF 6 290 Negative 2 0 Increase in SCC, no pathogen identified
1 LF 8 670 Staphylococcus aureus 1 1 Increase in SCC, pathogen identified: Staph. aureus
1 LF 10 456 Staph. aureus 2 0 At risk for new IMI, except Staph. aureus
1 RF 0 120 CNS 0 0 Low SCC, initial CNS IMI identified
1 RF 2 140 NC 2 0 At risk for all new IMI, except CNS
1 RF 4 754 Streptococcus uberis 1 1 Increase in SCC, new IMI with Strep. uberis
1 RF 5 — Strep. uberis 1 0 Clinical mastitis, not a new IMI
1 RF 6 250 Negative 1 0 At risk for new IMI, except CNS and Strep. uberis
1 RF 8 120 NC 2 0 At risk for new IMI, except CNS and Strep. uberis
1 RF 10 970 Staph. aureus 1 1 Increase in SCC, new IMI with Staph. aureus
1 RH 0 450 CNS 0 0 High initial SCC, and CNS IMI identified
1 RH 2 270 CNS 2 0 SCC remains high, CNS IMI, no new infection
1 RH 4 120 NC 2 0 At risk for new IMI, except CNS
1 RH 6 58 NC 2 0 At risk for new IMI, except CNS
1 RH 8 450 CNS 2 0 Increase in SCC, IMI with CNS, not a new IMI
1 RH 10 490 CNS 2 0 Increase in SCC, IMI with CNS, not a new IMI
1Cow = cow identification; Quarter = quarter identification (LF = left front; RF = right front; RH = right hind); Time = week in the trial; 
Bacteriology = culture results (NC = not cultured; CNS = Staphylococcus spp.); Week at risk = week at risk for a new IMI; New IMI = variable 
indicating whether a new infection has occurred in a given week. 
2A remark is provided for each observation to explain the coding used.
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Environmental temperature ranged between −12.3 and 
25.4°C. Milking equipment was checked twice, at the 
beginning and midway through the study. Both times 
the equipment fully met ISO standards. Teat disinfec-
tants were applied according to protocol without any 
evidence for protocol violations. Teat disinfectant usage 
was approximately 7 mL/cow per day.
The effect of the 2 premilking teat disinfectants (F-
2326 in EG and Theratec Plus in CG) was evaluated 
using information available from 4,017 quarter samples 
(Table 2). A total of 630 in CG and 587 in EG were 
cultured. Samples were cultured at study entry, calving, 
dry-off, exit, and during the trial when SCC was above 
the threshold value. A total of 1,374 (68.6%) and 1,426 
(70.8%) milk samples for CG and EG, respectively, did 
not meet these specifications; therefore, they were not 
submitted for bacteriological culture. Of all samples 
submitted for culture, 306 (CG) and 229 (EG) quarter 
milk samples met the qualifying requirements for bac-
teriological culture with the quarters having an SCC 
>100,000 cells/mL in first lactation cows or >200,000 
cells/mL in lactation 2 and higher cows. A total of 6 
cases of clinical mastitis were observed; 5 cases were in 
CG and 1 case in EG. All clinical cases were cultured; 4 
samples were culture negative, 2 samples cultured Esch-
erichia coli, and contributed 2 new IMI to the study.
Of the 1,217 milk samples cultured, 1,044 (85.8%) 
did not show bacterial growth. Bacteria were isolated in 
13.3% of CG (84/630), and 12.4% of EG (73/587). Isola-
tions of Staphylococcus spp. accounted for 69 (43.9%) of 
positive samples, followed by Staphylococcus aureus (25; 
15.9%). Streptococcus uberis was frequently isolated in 
the CG (18 samples), but not in EG (2 samples). The 
vast majority of bacterial pathogens were identified 
in samples with a SCC value above the threshold. All 
results are shown in Table 2.
Incidence of New IMI
The incidence rate of having a new IMI was calcu-
lated based only on the information available for the 
quarters sampled during the study period. The effect of 
2 premilking teat disinfectants on the risk of new IMI 
was evaluated based on a total of 6,273 quarter-weeks 
at risk, 3,109 in CG and 3,164 in EG (Tables 3 and 4). 
The overall rate of new IMI was 0.55 (SE = 0.13) and 
0.44 (SE = 0.12) new IMI per 100 quarter-weeks at risk 
in the CG and EG, respectively. Therefore, the relative 
rate of new IMI was 1.25 times higher in the CG com-
pared with the EG, resulting in a relative efficacy of the 
experimental dip compared with the control product 
of 19%. The Poisson regression model converged and 
Table 2. Isolation of mastitis pathogens in quarter milk samples collected from cows treated with different pre- and postmilking teat disinfectants1 
Sample status
All samples Samples above SCC threshold
Theratec Plus2  
(control)
F-23263  
(experimental)
Theratec Plus2  
(control)
F-23263 
(experimental)
No. % No. % No. % No. %
Samples cultured 630 31.4 587 29.2 306 100.0 229 100.0
Culture negative 542 27.0 502 24.9 225 73.5 155 67.7
Culture positive 84 4.2 73 3.6 81 26.5 71 31.0
Streptococcus spp. 2 0.1 1 0.0 2 0.7 1 0.4
Streptococcus dysgalactiae 4 0.2 7 0.3 4 1.3 7 3.1
Streptococcus uberis 18 0.9 2 0.1 18 5.9 2 0.9
Staphylococcus aureus 12 0.6 13 0.6 12 3.9 13 5.7
Staphylococcus spp. 35 1.7 34 1.7 34 11.1 34 14.8
Corynebacterium spp. 0 0.0 0 0.0 0 0.0 0 0.0
Gram-positive bacillus 0 0.0 1 0.0 0 0.0 0 0.0
Escherichia coli 6 0.3 6 0.3 4 1.3 6 2.6
Klebsiella spp. 0 0.0 0 0.0 0 0.0 0 0.0
Pasteurella spp. 5 0.2 0 0.0 5 1.6 0 0.0
Serratia spp. 0 0.0 1 0.0 0 0.0 0 0.0
Citrobacter spp. 2 0.1 0 0.0 2 0.7 0 0.0
Enterobacter spp. 0 0.0 0 0.0 0 0.0 0 0.0
Trueperella pyogenes 0 0.0 3 0.1 0 0.0 3 1.3
Prototheca spp. 0 0.0 0 0.0 0 0.0 0 0.0
Yeast 0 0.0 5 0.2 0 0.0 5 2.2
Contaminated 4 0.2 12 0.6 0 0.0 3 1.3
Samples not cultured4 1,374 68.6 1,426 70.8     
Total, all samples 2,004 100.0 2,013 100.0     
1Results are shown for all samples and for samples with an SCC value above the defined threshold.
2Theratec Plus, GEA Farm Technologies Inc., Naperville, IL.
3DeLaval Inc., Kansas City, MO.
4These samples did not meet the SCC selection criterion for culture or no milk was available for SCC and culture.
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showed a good fit to the data. Within-quarter correla-
tion was low, with a correlation coefficient of 0.007. In 
the Poisson regression model, the relative rate of new 
IMI during lactation, although numerically higher in 
CG, was not significantly different between the 2 treat-
ment groups (P = 0.57). Time had a significant effect 
on the overall rate of new IMI (P < 0.05), with a de-
creasing trend of new IMI over the course of the 10-wk 
study (Table 4). The interaction of treatment by time 
was not significant (P > 0.50). The least squares means 
of the rate of new IMI for the 2 treatment groups are 
shown in Figure 2.
As the trial did not show a significant difference 
between CG and EG, the goal then was to identify 
whether the conclusion of no difference may result 
in a noninferiority claim. The claim of noninferiority 
was based on the right-hand side of the 95% CI of the 
rate difference being smaller than the predefined non-
inferiority limit of d. In this study, d was defined at 
0.6 × rate of new IMI in the positive control group. 
Therefore, the critical value was 0.6 × 0.55 = 0.33 new 
IMI/100 quarter-weeks. The rate difference and 95% 
CI are shown in Table 4. The rate difference was −0.10 
with the upper bound of the 95% CI at 0.24. The up-
per bound of the CI was therefore below the critical 
value, d. Thus, it can be concluded that noninferiority 
of the experimental premilking disinfectant relative to 
the control was shown (Figure 3).
Based on the observed rate of new IMI in the control 
group, the defined value of d, the critical noninferiority 
difference, and the actual sample size, the actual power 
of the study was calculated. The actual power when the 
true difference between the 2 disinfectants was assumed 
to be 0, and the rate of new IMI in the control group 
of 0.55 new IMI/100 quarter-weeks with approximately 
3,100 observations per treatment group was estimated 
at 0.55. The within-cow correlation of new IMI was low 
and estimated at 0.02.
Effect on SCC
A total of 4,017 quarter milk samples were collected 
between 0 and 10 wk after the start of the trial. Of 
these, 3,960 were analyzed for SCC. Fifty-seven val.
Table 3. Number of new IMI and quarters at risk for an IMI on a biweekly basis1  
Treatment 0 2 4 6 8 10 Total
Control group        
 New IMI  7 3 3 4 0 17
 Quarter-week at risk 0 729 705 627 546 502 3,109
Experimental group        
 New IMI  7 4 1 2 0 14
 Quarter-week at risk 0 713 700 631 602 518 3,164
1The incidence rate of all quarters is calculated over the total new IMI and total quarters at risk.
Table 4. Incidence of new IMI of mastitis pathogens in longitudinally collected quarter milk samples from 
cows treated with different pre- and postmilking teat disinfectants 
Sample status (no.)
Theratec Plus1  
(control)
F-23262  
(experimental)
Quarter-wk at risk 3,109 3,164
 New IMI 17 14
 Streptococcus spp. 2 1
 Streptococcus dysgalactiae 2 1
 Streptococcus uberis 2 0
 Staphylococcus aureus 4 0
 Staphylococcus spp. 3 6
 Corynebacterium spp. 0 0
 Gram-positive bacillus 0 0
 Escherichia coli 3 3
 Klebsiella spp. 0 0
 Pasteurella spp. 0 0
 Serratia spp. 0 0
 Citrobacter spp. 1 0
 Trueperella pyogenes 0 1
 Prototheca spp. 0 0
 Yeast 0 2
Rate of new IMI per 100 quarter-week (95% CI) 0.55 (0.31, 0.88) 0.44 (0.24, 0.74)
Rate difference (95% CI) −0.10 (−0.45, 0.24)
Experimental disinfectant efficacy 19%
1Theratec Plus, GEA Farm Technologies Inc., Naperville, IL.
2DeLaval Inc., Kansas City, MO.
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ues were missing because too little milk was present, 
samples were clinical, or samples were lost for other 
reasons. Mean SCC in all samples was 274,000 cells/
mL, with a geometric mean SCC of 28,000 cells/mL. 
The SCC values ranged between 1,000 and 20,105,000 
cells/mL. No differences in overall mean SCC were 
observed between CG and EG (P = 0.21). However, a 
slight but statistically significant increase in SCC was 
observed during the trial (P < 0.01). Also, the inter-
action between treatment and time was significant (P 
= 0.01), and further evaluation indicated that SCC in 
milk from quarters in CG at the beginning and at the 
end of the trial was significantly higher compared with 
the EG (Figure 4). In the linear model, the longitudinal 
within-quarter correlation of SCC over the study was 
approximately 0.25, and the within-sample day cross-
sectional correlation within cow was also estimated at 
approximately 0.25, clearly showing a high correlation 
of SCC measurements over time in the same quarter 
and within the same mammary gland at any given 
point in time.
DISCUSSION
The major objective of the study described herein 
was to evaluate the feasibility of performing nonin-
feriority studies on premilking teat disinfectants on 
commercial dairy farms, using a novel 2-step diagnostic 
process for the detection of new IMI. The study showed 
sufficient new IMI and very small differences between 
the experimental product and positive control product, 
such that a conclusion of noninferiority could be drawn 
from the results.
These results were obtained using a novel 2-step di-
agnostic process that allowed the study to be completed 
in a reasonable time frame, with a targeted use of the 
more precise and expensive diagnostics, whereas a low 
cost screening test was used extensively. Eventually, 
approximately 4,000 samples were tested for SCC and 
30.7% of these samples were also tested using classi-
cal bacteriology. Compared with previously published 
trials (Oliver et al., 1993a; Peters et al., 2000; Oliver 
et al., 2001), our proposed noninferiority study with a 
2-step diagnostic process resulted in substantial savings 
while maintaining the ability to draw valid conclusions.
The use of a 2-step diagnostic process, as used in this 
protocol, is known as testing in series (i.e., high SCC 
and culture positive) and is therefore expected to result 
in an increased specificity and decreased sensitivity 
(Smith and Slenning, 2000; Dohoo et al., 2009). Given 
the low incidence of new IMI, a strategy to optimize 
specificity would be generally recommended (Smith 
and Slenning, 2000). The estimated loss in overall sen-
sitivity is approximately 20% (Schepers et al., 1997), 
resulting in fewer identified new IMI. The presence of 
diagnostic error that is identical across the 2 treat-
ments would be expected to introduce little, if any, bias 
in the estimation of the relative efficacy of the disinfec-
tants. However, diagnostic errors do introduce a bias in 
comparative studies where the bias generally results in 
Figure 2. Model-based least squares means (± SEM) of the inci-
dence rate of having a new IMI in all at-risk quarter-periods of cows 
from control group (ڏ) and experimental group (□).
Figure 3. Difference in the rate of new IMI between experimental and control disinfectant in the noninferiority trial, where the critical dif-
ference (d) is shown relative to the observed difference and associated 95% CI. Units are rate difference per 100 quarter-weeks.
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an efficacy estimate that is closer to 1 (Morant et al., 
1988). Although the introduced bias due to diagnostic 
error was relatively small, it is of particular concern 
in noninferiority studies where the identification of a 
relative efficacy of 1 is the preferred outcome of the 
study. The estimated bias in efficacy estimates due to 
diagnostic error is small when the true relative efficacy 
is close to 1 (Morant et al., 1988); as the observed dif-
ference between the 2 treatments in the trial was small, 
we expect that the introduced bias due to diagnostic 
error is small. Additionally, in the current study, the 
sample size was corrected for the estimated loss in sen-
sitivity and the overall ability to identify a difference, 
if it was truly present, turned out to be acceptable. In 
hindsight, the duration of the trial could have been 
extended to improve the observed power. Still, the dif-
ference in new IMI favoring the experimental product 
eventually allowed a conclusion of noninferiority.
Keeping track of new IMI and time at risk is essential 
to estimate the rate of new IMI in each treatment group. 
Even though we used biweekly sampling, the unit of 
time in our analysis was weeks. By choosing biweekly 
sampling rather than weekly sampling, the rate of new 
IMI will be lower, as many short-term infections will be 
missed. This principle is shown in Figure 5. Quarters 1, 
3, 4, and 5 have an observed new IMI, whereas quarters 
2 (2 new IMI), 3, 5, and 6 have a new IMI that occurs 
between samplings and is short in duration so that it 
is missed by the biweekly sampling scheme. Note that 
both in the first and second week between samplings, 
new IMI occur that can be observed; in quarter 4, a new 
IMI occurs in wk 3, whereas, in quarter 5, a new IMI 
occurs in wk 5. Hence, both weeks are potentially at 
risk for new IMI. In reality, the actual time of new IMI 
is not observed, and therefore all new IMI are assumed 
to occur at the midpoint between samplings. After the 
IMI occurs, the quarter is not at risk for a new IMI for 
1 wk, as indicated by a hashed bar in Figure 5. After 1 
wk a new IMI can occur with a different bacterial spe-
cies than the one observed in previous IMI. Quarters at 
risk are also counted in Figure 5. In the case of biweekly 
sampling, the observed rate of new IMI will be 4 per 43 
quarter-weeks at risk. In the case of weekly sampling 
the observed rate would be 8 per 43 quarter-weeks at 
risk. The denominator is the same as with the weekly 
sampling, with only 0.5 wk at risk lost after a new 
IMI. Hence, with more frequent sampling, the required 
sample size may be smaller, as a higher rate of new IMI 
is likely observed (Wickramaratne 1995).
A high efficacy of iodine-based premilking teat disin-
fectants against most of the environmental and conta-
gious pathogens has been reported after experimental 
challenges or natural exposure studies (NMC, 2013). 
Previous studies have reported an adequate efficacy 
of iodine disinfectants (Pankey et al. 1987; Oliver et 
al., 1993b); our results indicated that the iodine-based 
experimental product compared favorably with the 
iodine-based control disinfectant in reducing the rate of 
new IMI in a commercial dairy herd using a noninferi-
ority study design. Although not tested here, it may be 
expected that both products would reduce the rate of 
new IMI relative to a negative control.
Although the study focuses on all new IMI across 
bacterial species, the distribution of bacterial species 
in the 2 groups is of interest. As shown in Table 2, 
the difference between CG and EG in bacterial spe-
cies profile is remarkably similar. Possible exceptions 
include a higher proportion of Streptococcus uberis and 
Pasteurella spp. in CG and Truepurella pyogenes and 
yeast in EG. The overall prevalence in IMI was virtu-
ally identical in both treatment groups, which is prob-
ably the most important parameter to evaluate given 
the potential transmission of pathogens between cows 
within a treatment group.
The current NMC protocol for evaluation of premilk-
ing teat disinfectants (Hogan et al., 1991) is in need of 
a rewrite. The defined protocol does not address the 
issues recently identified by Schukken et al. (2013) with 
regard to postmilking teat disinfectant efficacy estima-
tion. Among other issues, the protocol does not address 
positive control trials, noninferiority, quality assurance 
in data collection, power calculations, or standardized 
reporting. The studies, as reported herein, may serve 
as a template for the development of the next genera-
tion of such a standardized protocol for evaluation of 
premilking teat disinfectants.
In the description of the statistical analysis of the 
data, both Poisson regression and logistic regression 
were indicated as options. Poisson regression appears 
to be the more natural choice for data on the rate of 
new IMI. However, our experience is that convergence 
Figure 4. Model-based least squares means (± SEM) of log10 SCC 
in milk from all quarters in the control (ڏ) and experimental groups 
(□).
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of Poisson models is not always reached and, in such 
situations, logistic regression is more robust (Schukken 
et al., 2010). Logistic regression is used with the out-
come variable defined as events or trials, which in teat 
disinfectant studies would be new IMI/weeks at risk; 
for most of our data that would be 0/2 and, in some 
cases, 1/2 or even 2/2 IMI/weeks at risk.
When defining a standard protocol for evaluation of 
premilking teat disinfectants a few critical issues would 
need to be defined. In this study, we defined the re-
quired efficacy of premilking disinfectants to be used as 
positive controls relative to no disinfectant used as, at 
least, 50%. Several disinfectants meeting this require-
ment have been reported (NMC, 2013). To define the 
noninferiority limit (d), the minimal acceptable efficacy 
of a premilking teat disinfectant was defined at 20%. 
Although this minimum efficacy is lower than the 
minimal efficacy used for postmilking teat disinfection 
(Schukken et al., 2013), the difference between the ef-
ficacy of the positive control to the minimal acceptable 
efficacy is identical to what was defined for postmilk-
ing teat disinfection at 30 percentage points (70–40 vs. 
50–20%, respectively). It is important to keep in mind 
that the minimal acceptable efficacy refers to the left-
hand side of the 95% CI. Therefore, for any reasonable 
sample size, the actual point estimate of efficacy of a 
test product in a noninferiority trial will need to be 
relatively close to the positive control product. It will 
be important for the major partners in the area of teat 
disinfectants to consider the arguments brought forward 
in this report and define the acceptable noninferiority 
limit (d) to be used in future trials.
CONCLUSIONS
A field trial with naturally occurring IMI evaluating 
an experimental premilking teat disinfectant against 
a positive control was conducted, and noninferiority 
of the experimental product relative to the positive 
control was shown. A novel 2-step diagnostic process 
was used to identify new IMI. This diagnostic proto-
col resulted in a more economical and efficient way to 
identify new IMI. The described protocol may serve as 
a template for future trials and for the definition of a 
standardized efficacy evaluation protocol for premilk-
ing teat disinfectants.
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